Citi Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $60
Structure Draws New Buy at Citi on Oral Obesity Drug Pipeline
Citigroup Initiates Coverage on Structure Therapeutics With Buy Rating, $60 Price Target
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $80
Structure Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Structure Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Buy Rating for Structure Therapeutics: Aleniglipron's Competitive Edge in the Oral GLP-1 Market
Structure Therapeutics Analyst Ratings
SA Asks: What's the Best Weight-loss Drug Stock Right Now?
UniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
JPMorgan Says Lilly Data 'Highly Favorable' for Structure Therapeutics
Express News | Shares of Obesity Drug Developer Structure Therapeutics up 24.6% Premarket After Eli Lilly's Pill Leads to 7.9% Weight Loss in Late-Stage Trial
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $87
OpenFold AI Research Consortium Welcomes New Members Including Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind, Unnatural Products, and Visterra
Pfizer (PFE.US) facing setbacks in research sparks acquisition speculation, stocks of the new weight loss drug rising sharply.
Pfizer (PFE.US) has stopped the development of the highly anticipated oral weight loss drug Danuglipron. Investors are betting that this setback may prompt Pfizer to seek acquisition trades, leading to a rise in the stock prices of several biotechnology companies developing weight loss drugs on Monday.
Wegovy, Zepbound Makers' Stocks Rally as a Weight-loss-drug Competitor Drops Out
Viking, Structure, Metsera on a Tear as Pfizer Drops Obesity Pill
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Trending Stocks Today | Tenon Medical Surges 51.33% Post-Market